Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, today announced that it is hosting an investor and analyst event on Friday, November 8, 2019 from 6:00 – 7:30 pm ET, during the Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, Maryland. The event will be hosted by Corvus president and CEO, Dr. Richard Miller, and will include featured guest Jason J. Luke, M.D., principal investigator of the CPI-006 Phase 1/1b clinical trial and other investigators participating in clinical trials of ciforadenant and the adenosine gene signature in renal cell cancer.
BURLINGAME, Calif., May 13, 2020 -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of.
We can readily understand why investors are attracted to unprofitable companies. For example, although...
BURLINGAME, Calif., Nov. 05, 2019 -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of.
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
Corvus (CRVS) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BURLINGAME, Calif., Feb. 28, 2020 -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of.
Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel biomarkers to enhance patient selection, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2019. “In 2019, we continued to efficiently advance our pipeline and exited the year with three candidates in clinical trials,” said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus.
Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, today announced updated results from its Phase 1/1b trial of CPI-006, the Company’s anti-CD73 antibody. The clinical data continue to support a novel mechanism of action involving the activation of immune cells potentially directed against tumors, along with the inhibition of adenosine production.
BURLINGAME, Calif., April 22, 2020 -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization.
Q4 2019 Corvus Pharmaceuticals Inc Earnings Call
BURLINGAME, Calif., Nov. 07, 2019 -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of.
Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, announced initial results from its Phase 1/1b trial of CPI-818, the Company’s ITK-inhibitor. The results were presented in a poster at the American Society of Hematology (ASH) 61st Annual Meeting 2019 in Orlando, Florida, taking place December 7-10, 2019. “We are excited to report the first clinical experience with CPI-818, our selective covalent ITK inhibitor designed to address T-cell lymphomas, a category of hematologic cancers with great need for novel therapeutic options,” said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus.
Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, announced updated results from its Phase 1/1b clinical trial of CPI-818, the Company’s ITK-inhibitor, which were presented today in an oral presentation at the 12th Annual T-Cell Lymphoma Forum in La Jolla, California, taking place January 30 to February 1, 2020. “Our Phase 1/1b clinical trial of CPI-818, our selective covalent ITK inhibitor designed to address T-cell lymphomas, is enrolling well and continues to provide promising clinical data for patients with advanced, refractory forms of this cancer,” said Mehrdad Mobasher, M.D., chief medical officer of Corvus.
BURLINGAME, Calif., May 27, 2020 -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of.
With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the second quarter. One of these stocks was Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS). Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) shareholders have […]
Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel biomarkers to enhance patient selection, today provided a business update and announced financial results for the first quarter ended March 31, 2020. “In the first quarter, we continued enrolling patients across our three clinical stage programs and reported positive data updates for ciforadenant, the Adenosine Gene Signature, and CPI-818,” said Richard A. Miller, M.D., president and chief executive officer of Corvus.
Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, was awarded with the 2020 Drug Hunter Award on February 11, 2020 by the UC Drug Discovery Consortium in a ceremony held at the University of California, San Francisco (UCSF). This annual award and lecture series is sponsored by the UC Drug Discovery Consortium, UCSF Innovation Ventures, the Center for Drug Discovery Innovation, and the law firm of Wilson Sonsini Goodrich & Rosati.
Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, announced updated results from its Phase 1b/2 clinical trial of ciforadenant, an adenosine A2A receptor antagonist, in patients with metastatic castration resistant prostate cancer (mCRPC). The data were presented today in a poster presentation at the American Society of Clinical Oncology 2020 Genitourinary Cancers Symposium (ASCO-GU) in San Francisco by Lawrence Fong, M.D., study investigator and leader of the Cancer Immunotherapy Program at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center.
Q1 2020 Corvus Pharmaceuticals Inc Earnings Call